A Phase Ⅰb/Ⅱ Clinical Study of SHR-A1811 Combined With Other Therapies in Patients With HER2 Low Advanced or Metastatic Breast Cancer.

NCT05792410 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

300

Enrollment

INDUSTRY

Sponsor class

Conditions

HER2 Low Advanced or Metastatic Breast Cancer

Interventions

DRUG: SHR-A1811 & Dalpiciclib Isethionate Tablets
DRUG: SHR-A1811 & Fulvestrant
DRUG: SHR-A1811 & Bevacizumab injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.